A new CDC report shows that infections caused by multi-drug-resistant bacteria known colloquially as “nightmare bacteria” surged in the United States from 2019 to 2023. Carbapenem-resistant ...

A new report from the Centers for Disease Control and Prevention on the deadly drug-resistant bacteria NDM-CRE found a 70% rise in infections in the U.S. between 2019 and 2023. Also known as ...

Infections caused by a drug-resistant bacteria once considered uncommon are surging in the United States, a new Centers for Disease Control and Prevention study finds. These so-called "nightmare" ...

Add Yahoo as a preferred source to see more of our stories on Google. Difficult-to-treat infections caused by dangerous, drug-resistant bacteria are on an alarming upward climb, the Centers for ...

An oral antibiotic treatment with nonabsorbable drugs may help eradicate Carbapenem-resistant Enterobacteriaceae colonization, according to a study published in the American Journal of Infection ...

"Superbug" bacteria that are resistant to antibiotics have the potential to create a nightmare scenario for modern medicine, but experts are hopeful that doctors will be able to slow the spread of ...

The CDC reported a surge in NDM-CRE, a dangerous bacteria that is “resistant to some of the strongest antibiotics” The agency said there was a 460% increase in infections of NDM-CRE in the United ...

CORRECTED September 30, 2025 // An earlier version of this article incorrectly stated the two drugs which are effective against NDM-CRE. The article has been updated to state aztreonam-avibactam and ...

Carbapenem-resistant Enterobacterales (CRE), including carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Escherichia coli, pose a major risk to patients and healthcare systems in the ...

Research out of Chicago-based Rush University Medical Center suggests children are becoming infected with the superbug carbapenem-resistant Enterobacteriaceae much more frequently than in the recent ...

Purpose. The chemistry, pharmacology, antimicrobial activity, pharmacokinetics, pharmacodynamics, efficacy and safety in humans, and formulary considerations of doripenem are reviewed. Summary.